Jew, O. S., Liu, W. W., Stamey, C., Kheterpal, M., Myers, S. A., Ellis, M. J., … Whitley, M. J. (2024). De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy. J Am Acad Dermatol, 91(4), 720–722. https://doi.org/10.1016/j.jaad.2024.05.068

Jew, Olivia S., Winston W. Liu, Christopher Stamey, Meenal Kheterpal, Sarah A. Myers, Matthew J. Ellis, Jennifer Byrns, Lee Wheless, and Melodi Javid Whitley. “De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy.” J Am Acad Dermatol 91, no. 4 (October 2024): 720–22. https://doi.org/10.1016/j.jaad.2024.05.068.

Jew OS, Liu WW, Stamey C, Kheterpal M, Myers SA, Ellis MJ, et al. De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy. J Am Acad Dermatol. 2024 Oct;91(4):720–2.

Jew, Olivia S., et al. “De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy.” J Am Acad Dermatol, vol. 91, no. 4, Oct. 2024, pp. 720–22. Pubmed, doi:10.1016/j.jaad.2024.05.068.

Jew OS, Liu WW, Stamey C, Kheterpal M, Myers SA, Ellis MJ, Byrns J, Wheless L, Whitley MJ. De novo belatacept does not reduce the rate of skin cancer in renal transplant recipients compared to standard therapy. J Am Acad Dermatol. 2024 Oct;91(4):720–722.